DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
Table 3
Cardiovascular parameters based on echocardiography in dogs experimentally infected with T. cruzi and treated with the DNA vaccine containing genes encoding a trans-sialidase protein (pBCSP), an amastigote-specific glycoprotein (pBCSSP4), or both as a mixture.
Group
Left ventricular (LV) diastolic diameter (mm)
Left ventricular (LV) systolic diameter (mm)
Fractional shortening (FS) (%)
Left ventricular ejection fraction (LVEF) (%)
Posterior wall (mm)
Septum (mm)
Left atrium (LA) diameter/aorta root (AR) diameter ratio
Healthy
Inf/SS mock-treated
pBCSSP4
pBCSP
Mixture
pBK-CMV
Group descriptions are shown in Table 1. Inf = infected. All data are expressed as the means and standard deviations. Significant difference () between the treatment groups and the healthy dogs and/or with reference values [80].